Manufacturer of Controlled Substances; Notice of Application, 54929-54930 [E7-19099]

Download as PDF Federal Register / Vol. 72, No. 187 / Thursday, September 27, 2007 / Notices Consent Decree Library at the stated address. Robert E. Maher, Jr., Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 07–4741 Filed 9–26–07; 8:45 am] BILLING CODE 4410–15–M DEPARTMENT OF JUSTICE rwilkins on PROD1PC63 with NOTICES Notice of Lodging Consent Decree Under the Comprehensive Environmental Response, Compensation and Liability Act Notice is hereby given that on September 13, 2007, a proposed Consent Decree in United States of America v. Darcars of New Carrollton, Inc., Civil Action No. 2:07–cv–1235 was lodged with the United States District Court for the Western District of Pennsylvania. In this action the United States sought to recover response costs from the defendant incurred by the United States in responding to releases or threatened releases of hazardous substances at or from the Breslube Penn Superfund Site (the ‘‘Site’’) which is located in Moon Township, Allegheny County, Pennsylvania. The proposed Consent Decree resolves the liability of Darcars of New Carrollton, Inc. (‘‘Darcars’’), under Section 107(a)(3) of the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), 42 U.S.C. 9607(a)(3). Based on the amount of waste Darcars contributed to the Site, and EPA’s volumetric ranking of waste at the Site, Darcars will pay $2,720.83 to resolve its liability. Darcars had timely expressed an intention to participate in the Third Round De Minimus Consent Decree entered by the Court on May 5, 2006, but was inadvertently excluded from that settlement. The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and either e-mailed to pubcomment-ees.enrd@usdoj.gov or mailed to P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to United States of America v. Darcars of New Carrollton, Inc., D.J. Ref. 90–11–3–1762/ 5. The Consent Decree may be examined at the Office of the United States Attorney, Western District of Pennsylvania, 700 Grant Street, Suite 400, Pittsburgh, PA 15219, and at U.S. VerDate Aug<31>2005 16:40 Sep 26, 2007 Jkt 211001 EPA Region 3, 1650 Arch Street, Philadelphia, PA 19103. During the public comment period, the Consent Decree, may also be examined on the following Department of Justice Web site, to https://www.usdoj.gov/enrd/ Consent_Decrees.html. A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing or e-mailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 514–0097, phone confirmation number (202) 514–1547. In requesting a copy from the Consent Decree Library, please enclose a check in the amount of $6.50 (25 cents per page reproduction cost) payable to the U.S. Treasury or, if by e-mail or fax, forward a check in that amount to the Consent Decree Library at the stated address. Robert Brook, Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 07–4745 Filed 9–26–07; 8:45 am] BILLING CODE 4410–15–M DEPARTMENT OF JUSTICE Notice of Lodging of Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (‘‘CERCLA’’) Consistent with Section 22(d) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (‘‘CERCLA’’), 42 U.S.C. 9622(d), and 28 CFR 50.7, notice is hereby given that on September 14, 2007, a proposed Consent Decree with NextiraOne, LLC, d/b/a Black Box Network Services, and Report Investment Corporation, in United States v. NextiraOne, LLC, et al., Civ. No. 07–20654, was lodged with the United States District Court for the Southern District of Florida, Miami Division. In this action, the United States seeks under Section 122 of CERCLA to enforce obligations in two administrative orders to pay past and oversight costs incurred by the United States in responding to the release and/or threatened release of hazardous substances at and from the Anaconda Aluminum Co./Milgo Electronics Corp. National Priorities List Site (‘‘Site’’) in Miami, Florida. Under the proposed Consent Decree, the Defendants will pay $325,000.00 to the Hazardous Substances Superfund in reimbursement of the costs incurred by the United States at the Site. PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 54929 The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to United States v. NextiraOne, LLC, et al., (S.D. Fla.) (DOJ Ref. Nos. 90–11–2–07899/1 and 90–11–2–07899/3). The Consent Decree may be examined at the Office of the United States Attorney, Southern District of Florida, 99 NE. 4th Street, Miami, Florida 33132–2111 (contact Ann M. St. PeterGriffith, Esq., 305–961–9419), and at U.S. EPA Region 4, Atlanta Federal Center, 61 Forsyth Street, SW., Atlanta, Georgia 30303 (contact Nadine Orrell, Esq., 404–562–9701). During the public comment period, the Consent Decree may also be examined on the following Department of Justice Web site, https:// www.usdoj.gov/enrd/ Consent_Decrees.html. A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, U.S. Department of Justice, P.O. Box 7611, Washington, DC 20044–7611 or by faxing or e-mailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 514–0097, phone confirmation number (202) 514–1547. In requesting a copy from the Consent Decree Library, please refer to United States v. NextiraOne, LLC, et al., (S.D. Fla.) (DOJ Ref. Nos. 90–11–2–07899/1 and 90–11–2–07899/3), and enclose a check in the amount of $4.00 (25 cents per page reproduction cost) payable to the U.S. Treasury or, if by e-mail or fax, forward a check in that amount to the Consent Decree Library at the stated address. Ellen Mahan, Deputy Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 07–4743 Filed 9–26–07; 8:45 am] BILLING CODE 4410–15–M DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 21, 2007, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration E:\FR\FM\27SEN1.SGM 27SEN1 54930 Federal Register / Vol. 72, No. 187 / Thursday, September 27, 2007 / Notices (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug I I II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than November 26, 2007. Dated: September 21, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–19099 Filed 9–26–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration rwilkins on PROD1PC63 with NOTICES Importer of Controlled Substances; Notice of Application Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on August 30, 2007, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II: Drug Schedule Methamphetamine (1105) ............ 16:40 Sep 26, 2007 Schedule Phenylacetone (8501) .................. Raw Opium (9600) ....................... Concentrate of Poppy Straw (9670). II II II Schedule Tetrahydrocannabinols (7370) ..... Dihydromorphine (9145) ............... Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Remifentanil (9739) ...................... VerDate Aug<31>2005 Drug II Jkt 211001 Dated: September 21, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–19100 Filed 9–26–07; 8:45 am] BILLING CODE 4410–09–P The company plans to import the listed controlled substances to manufacture bulk controlled substances for sale to its customers. No comments, objections, or requests for any hearings will be accepted on any application for registration or reregistration to import crude opium, [Raw Opium (9600)], poppy straw, concentrate of poppy straw, and coca leaves. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 29, 2007. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 24, 2007, ISP Freetown Fine Chemicals, 238 South Main Street, Assonet, Massachusetts 02702, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug 2,5-Dimethoxyamphetamine (7396). Amphetamine (1100) .................... Phenylacetone (8501) .................. Schedule I II II The company plans to manufacture Phenylacetone to be used in the manufacture of Amphetamine for distribution to its customers. The bulk 2,5-Dimethoxyamphetamine will be used for conversion into non-controlled substances. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than November 26, 2007. Dated: September 21, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–19131 Filed 9–26–07; 8:45 am] BILLING CODE 4410–09–P E:\FR\FM\27SEN1.SGM 27SEN1

Agencies

[Federal Register Volume 72, Number 187 (Thursday, September 27, 2007)]
[Notices]
[Pages 54929-54930]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-19099]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 21, 2007, Cedarburg 
Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, 
made application by renewal to the Drug Enforcement Administration

[[Page 54930]]

(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule I and II:

 
------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
Dihydromorphine (9145).....................  I
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
Remifentanil (9739)........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 2401 
Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed 
no later than November 26, 2007.

    Dated: September 21, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-19099 Filed 9-26-07; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.